Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging...
Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study
About this item
Full title
Author / Creator
Selmaj, Krzysztof, Prof , Li, David KB, Prof , Hartung, Hans-Peter, Prof , Hemmer, Bernhard, Prof , Kappos, Ludwig, Prof , Freedman, Mark S, Prof , Stüve, Olaf, MD , Rieckmann, Peter, Prof , Montalban, Xavier, Prof , Ziemssen, Tjalf, MD , Auberson, Lixin Zhang, MD , Pohlmann, Harald, MSc , Mercier, Francois, PhD , Dahlke, Frank, MD and Wallström, Erik, MD
Publisher
England: Elsevier Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: Elsevier Ltd
Subjects
More information
Scope and Contents
Contents
Summary Background Siponimod is an oral selective modulator of sphingosine 1-phosphate receptor types 1 and type 5, with an elimination half-life leading to washout in 7 days. We aimed to determine the dose-response relation of siponimod in terms of its effects on brain MRI lesion activity and characterise safety and tolerability in patients with r...
Alternative Titles
Full title
Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study
Authors, Artists and Contributors
Author / Creator
Li, David KB, Prof
Hartung, Hans-Peter, Prof
Hemmer, Bernhard, Prof
Kappos, Ludwig, Prof
Freedman, Mark S, Prof
Stüve, Olaf, MD
Rieckmann, Peter, Prof
Montalban, Xavier, Prof
Ziemssen, Tjalf, MD
Auberson, Lixin Zhang, MD
Pohlmann, Harald, MSc
Mercier, Francois, PhD
Dahlke, Frank, MD
Wallström, Erik, MD
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1560103605
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1560103605
Other Identifiers
ISSN
1474-4422
E-ISSN
1474-4465
DOI
10.1016/S1474-4422(13)70102-9
